HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Selumetinib | Koselugo | 10mg, 25mg | Chemotherapy | MEK Inhibitor | MEK 1/2 | Yes | 2020 | In Use | |||
NA | Binimetinib | Mektovi | 15mg | Chemotherapy | MEK Inhibitor | MEK 1/2 | Yes | 2018 | In Use | |||
J9030 | Bacillus calmette-guerin | BCG Vaccine, Tice BCG | 1mg | Immunotherapy | Biological Response Modifier | Live Vaccine | No | 1990 | Jul 1, 2019 | In Use | ||
C9416 | BCG | BCG, Intravesical | Per instillation | Immunotherapy | Biological Response Modifier | Live Vaccine | No | 1990 | Jan 1, 2004 | Dec 31, 2003 | No Longer Used | |
J9031 | Bacillus calmette-guerin substrain nice live antigen | Theracys, BCG Vaccine | Per instillation | Immunotherapy | Biological Response Modifier | Live Vaccine | No | 1990 | Jan 1, 1991 | Jul 1, 2019 | No Longer Used | |
J0128 | Abarelix | Plenaxis | 10 mg | Hormonal Therapy | Androgen Receptor Inhibitor | LHRH antagonist | No | 2003 | 2005 | Jan 1, 2005 | No Longer Used | |
C9216 | Abarelix | Plenaxis | 10 mg | Hormonal Therapy | Androgen Receptor Inhibitor | LHRH antagonist | No | 2003 | 2005 | Jan 1, 2005 | No Longer Used | |
S0165 | Abarelix | Plenaxis | 100 mg | Hormonal Therapy | Androgen Receptor Inhibitor | LHRH antagonist | No | 2003 | 2005 | Jan 1, 2005 | No Longer Used | |
NA | Sotorasib | Lumakras | Multiple | Chemotherapy | RAS Inhibitor | KRASG12C | Yes | 2021 | In Use | |||
Adagrasib | Krazati | 200mg | Immunotherapy | RAS Inhibitor | KrAS G12C | Yes | 2022 | In Use | ||||
NA | Ripretinib | Qinlock | 50mg | Chemotherapy | Tyrosine Kinase Inhibitor | KIT, PDGFRA | Yes | 2020 | In Use | |||
J2425 | Palifermin | Kepivance | 50 mcg | Ancillary Therapy | Epithelial Growth Factor | Keratinocyte Growth Factor/rHuKGF | No | 2004 | Jan 1, 2006 | In Use | ||
Pacritinib | Vonjo | 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | JAK2, FLT3 | Yes | 2022 | In Use | ||||
NA | Fedratinib Hydrochloride | Inrebic | 100mg | Chemotherapy | Enzyme Inhibitor | JAK2, FLT3 | Yes | 2019 | In Use | |||
NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 5 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
Momelotinib | Ojjaara | Multiple | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2023 | In Use | ||||
NA | Ruxolitinib | Jakafi | 20 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 15 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Ruxolitinib | Jakafi | 10 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
J9160 | Denileukin Diftitox | Ontak | 300 mcg | Immunotherapy | Cytokine | Interleukin-2 | No | 1999 | Jan 1, 2001 | In Use | ||
J9015 | Aldesleukin | Proleukin | Per single vial (1 vial = 22 million IU) | Immunotherapy | Cytokine | Interleukin-2 | No | 1992 | Oct 1, 1996 | In Use | ||
J9216 | Interferon Gamma-1b | Actimmune | 3 million units | Immunotherapy | Cytokine | Interferon | No | 1999 | Jan 1, 2009 | In Use | ||
S0145 | Pegintereferon Alfa-2a | Pegasys | 180 mcg/mL | Immunotherapy | Cytokine | Interferon | No | 2002 | Jul 1, 2005 | In Use | ||
J9213 | Interferon Alfa-2a | Roeferon- A | 3 million units | Immunotherapy | Cytokine | Interferon | No | 2002 | Jan 1, 2009 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.